Menu
Clinical Trial
Please contact us for more information or to learn if you are eligible to participate.
In this study we aim (1) to determine the tumor genomic landscape of NASH-associated Hepatocellular Carcinomas in patients in South Texas and, (2) to detect selected somatic mutations in plasma cfDNA in patients with NASH-associated Hepatocellular Carcinoma, using a custom-designed targeted sequencing panel.
| Principal Investigator | Jose Almeda, MD |
|---|---|
| Co-PI | |
| Sponsor | |
| Type of Trial | Prospective |
